Gut microbiome pattern impacts treatment response in primary biliary cholangitis.

Area of Science:

• Gastroenterology
• Immunology
• Microbiome Research

Background:

• Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease.
• Inadequate response to ursodeoxycholic acid (UDCA) is a significant risk factor for disease progression.
• Gut dysbiosis is increasingly recognized as a contributing factor in PBC pathogenesis.

Purpose of the Study:

• To identify microbial signatures for risk stratification in PBC patients.
• To investigate the mechanistic role of the gut microbiome in PBC.
• To explore potential novel therapeutic targets for PBC.

Main Methods:

• Prospective recruitment of UDCA treatment-naive PBC patients (n=132).
• Metagenomic sequencing and metabolomic profiling of stool and serum samples.
• Unsupervised machine learning for microbiome subtype identification and validation in independent cohorts.

Main Results:

• PBC baseline metagenomes clustered into two subtypes: Clostridia-high and Clostridia-low.
• Clostridia-low subtype showed a 2-fold higher UDCA non-response rate (41% vs. 20%).
• Reduced anaerobic fermentation and bioactive metabolite production (tryptophan derivatives, secondary bile acids) in Clostridia-low subtype.

Conclusions:

• Baseline gut microbiome patterns can predict UDCA treatment outcomes in PBC.
• Microbiome-based risk stratification may enable personalized treatment strategies for PBC.
• Targeting gut microbial dysbiosis could offer novel therapeutic avenues for PBC.